Viracta Therapeutics, Inc.
VIRX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 73.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -15,640.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -15,999.2% |
| EPS Diluted | -1.32 | -1.32 | -6.37 | -0.52 |
| % Growth | 0% | 79.3% | -1,125% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |